Age does not influence taxol dose intensity in recurrent carcinoma of the ovary

Background. In the treatment of advanced‐stage ovarian cancer, it is common practice to treat elderly patients in a less aggressive fashion than young patients. This approach is based on the notion that age is associated with poor patient tolerance to aggressive chemotherapy. Relatively little data exist to support this contention. The most exciting new chemotherapy agent to be developed in the last 10 years is taxol, a diterpeniod derivative of the Northwestern yew Taxus brevifolia.

[1]  T. Cornelison,et al.  Dose intensity analysis of high‐dose carboplatin in refractory ovarian carcinoma relative to age , 2010, Cancer.

[2]  F. Ognibene,et al.  Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  V. Devita.  The influence of information on drug resistance on protocol design. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[5]  D. Alberts,et al.  The role of cisplatin in the management of advanced squamous cell cancer of the cervix. , 1989, Seminars in oncology.

[6]  H. Lazarus,et al.  High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. , 1987, Seminars in oncology.

[7]  W. Hryniuk,et al.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Yancik,et al.  Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. , 1986, American journal of obstetrics and gynecology.

[10]  M. Greene,et al.  The epidemiology of ovarian cancer. , 1984, Seminars in oncology.

[11]  C. Begg,et al.  Clinical trials and drug toxicity in the elderly. The experience of the eastern cooperative oncology group , 1983, Cancer.

[12]  S. Rosenberg,et al.  The treatment of Hodgkin's disease. , 1966, The Medical clinics of North America.

[13]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .